← Leaderboards
William B Parker
Southern Research Institute
$3,366,132
Attributed
$3,366,132
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2005–13$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$12,723,851 · 7
By mechanism
U19$4,851,622 · 2
P01$4,734,498 · 2
R01$3,129,231 · 1
R13$8,500 · 2
Top collaborators
No co-investigators on record.
Most similar at Southern Research Institute
Same institution · by research overlap
- John A Secrist$6,038,272
- Rongbao Li$2,841,782
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionPurine AnalogPurine NucleosidesAntineoplasticsProdrugsNucleoside AnalogCooperative StudyPurine Nucleoside PhosphorylaseCytotoxicityEnzyme MechanismNeoplasm /Cancer PharmacologyMycobacterium TuberculosisAntitubercular AgentsEnzyme SubstrateDrug Screening /EvaluationDrug MetabolismAdenosineNew AgentsAnalogAntiviral AgentsNucleosidesBiologicalComplementLead
Grant awards (21)
2013 Nucleosides, Nucleotides, and Oligonucleotides Gordon Research Conference$5,000
R13 · FY2013 · AI · contact PI
2011 Nucleosides, Nucleotides, and Oligonucleotides GRC$3,500
R13 · FY2011 · CA · contact PI
Purine Analog Anti-Mycobacterial Drug Development$452,871
R01 · FY2009 · AI · contact PI
Purine Analog Anti-Mycobacterial Drug Development$453,972
R01 · FY2008 · AI · contact PI
Purine Analog Anti-Mycobacterial Drug Development$463,721
R01 · FY2007 · AI · contact PI
Purine Analog Anti-Mycobacterial Drug Development$478,491
R01 · FY2006 · AI · contact PI
Development of New Antitumor Agents$2,285,466
P01 · FY2005 · CA
Purine Analog Anti-Mycobacterial Drug Development$491,096
R01 · FY2005 · AI
Development of New Antitumor Agents$2,220,631
P01 · FY2004 · CA
TUMOR SENSITIZATION TO PURINE ANALOGS BY E.COLI PNP$1,094,836
U19 · FY2004 · CA
TUMOR SENSITIZATION TO PURINE ANALOGS BY E.COLI PNP$1,070,294
U19 · FY2003 · CA
TUMOR SENSITIZATION TO PURINE ANALOGS BY E.COLI PNP$1,031,218
U19 · FY2002 · CA
MECHANISM OF ACTION OF NUCLEOSIDE ANALOGS$228,401
P01 · FY2002 · CA
PURINE NUCLEOSIDE ANALOGS ACTIVATED BY E COLI PNP$0
U19 · FY2002 · CA
TUMOR SENSITIZATION TO PURINE ANALOGS BY E.COLI PNP$1,006,199
U19 · FY2001 · CA
PURINE ANALOG ANTIMYCOBACTERIAL DRUG DEVELOPMENT$400,369
R01 · FY2001 · AI
MECHANISM OF ACTION OF NUCLEOSIDE ANALOGS$0
P01 · FY2001 · CA
PURINE NUCLEOSIDE ANALOGS ACTIVATED BY E COLI PNP$0
U19 · FY2001 · CA
TUMOR SENSITIZATION TO PURINE ANALOGS BY E.COLI PNP$649,075
U19 · FY2000 · CA
PURINE ANALOG ANTIMYCOBACTERIAL DRUG DEVELOPMENT$388,711
R01 · FY2000 · AI
PURINE NUCLEOSIDE ANALOGS ACTIVATED BY E COLI PNP$0
U19 · FY2000 · CA